Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 5Neoplasms 3Colorectal Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 72Brachytherapy 31Radiotherapy 26Paclitaxel 23Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 21human papillomavirus vaccine, L1 type 16, 18 20Topotecan 18Papillomavirus Vaccines 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 16pembrolizumab 14Radiation 12Gemcitabine 12Early Intervention, Educational 12Colposcopy 12Methods 11Magnetic Resonance Spectroscopy 11atezolizumab 10Radiotherapy, Intensity-Modulated 10Blood Specimen Collection 10Papanicolaou Test 9Docetaxel 9Vaccines, Synthetic 8Platinum 8Nivolumab 8Ipilimumab 8Counseling 81,2-diaminocyclohexaneplatinum II citrate 8Vaccines 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Uterine Cervical Neoplasms × brivanib × Clear all
NCT01267253 2019-03-20

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

GOG Foundation

Phase 2 Completed
31 enrolled 9 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡